Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan With Palbociclib Versus Belzutifan Monotherapy in Advanced Renal Cell Carcinoma
NCT05468697Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of belzutifan, palbociclib in renal cell carcinoma (RCC), sponsored by Merck & Co.. Started Aug 2022; status: active, not recruiting.
02
Drugs
belzutifanpalbociclib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05468697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05468697.